Grants & giving

Strengthening Community-Driven Care

Submit an Application for a Medical Educational Grant

May 5, 2015

May 5, 2015

At Johnson & Johnson, we’re building a more inclusive and connected health system by supporting independent training and education initiatives. We are proud to provide grants that support eligible organizations in offering independent continuing medical education for healthcare professionals – including physicians, nurses, residents, and pharmacists – by enhancing their skills and knowledge in meeting the needs of patients and the community.

Requests for educational grants are evaluated consistent with appropriate internal and external guidelines and policies. We prioritize support in areas of therapeutic interest, and are particularly interested in initiatives that support communities facing barriers to equitable healthcare access and representation.

In addition, Johnson & Johnson may provide independent fellowship grants to eligible institutions and organizations to support advanced training opportunities for healthcare professionals. These grants are intended to help develop the next generation of healthcare leaders by fostering specialized clinical, research, and educational experiences that enhance professional growth and ultimately contribute to improved patient care.

Apply now:
Click here to visit our Grant Portal where you can submit a medical education grant.

New Hematology RFP:
2026 New Oncology Nursing Fellowship RFP Due Date November 13, 2026

Funding decisions:
Following an internal review process, you will be notified of the status of your application within 90 days of a completed submission and no additional information is required.

Delivery Methods:
Delivery methods vary per therapeutic area. They may include live and virtual activities, dinner programs, grand rounds, and on-site engagements with healthcare teams, ensuring our grants reach diverse audiences within the healthcare community.

Areas of interest:

Neuroscience

The Neurobiology of Mood Disorders

Understanding role dopamine, serotonin, and glutamate in MDD and BD
- NMDA and AMPA signaling in mood disorders
D1 receptor activity and downstream effects on glutamatergic signaling
Translating receptor pharmacology into clinical practice

Mood Disorders
Remission as the Treatment Goal

Why remission matters in MDD and BD
Early intervention strategies to improve patient outcomes
- Optimizing augmentation strategies following inadequate antidepressant response
- Reducing antidepressant cycling and treatment inertia
- Impact of treatment inertia on health economic and quality of life outcomes in patients with MDD and BD

Major Depressive Disorder (MDD)
Adjunctive Treatment Decision-Making

Comparative review of safety and efficacy of current approved treatments in Major Depressive Disorder (MDD)
Education on safety and efficacy of novel atypical antidepressant agents including topics such as comparative efficacy in MDD, cardiometabolic outcomes, weight gain, EPS, prolactin
Evidence-based augmentation in MDD
Positioning atypical antipsychotics in treatment algorithms

MDD with Anxious Distress

Recognition and treatment of anxious distress
Clinical implications of anxious distress in MDD
Diagnosis and treatment selection for patients with MDD and anxious distress
Functional burden and quality-of-life impact of anxious distress

Bipolar Disorder (BD)

Bipolar I, Bipolar II, Mania, Depression, Mixed features
- Advances in treatments, diagnosis, and burden of disease
  - FDA approved atypical Antipsychotic Indications for Bipolar I Disorder, Mania, Depression, and Mixed Features
- Under-recognition of Bipolar II - Differential diagnoses, approved treatments
- Comparative review of safety and efficacy of current approved treatments for BD I, BD II, and Mania
- Transitions of care in Bipolar Disorder – Acute Mania to Long term maintenance

Pediatric

Pediatric irritability in autism
Pediatric bipolar mania

Schizophrenia:

Earlier adoption of long-acting injectable antipsychotics (LAI) throughout the schizophrenia journey, including use during critical period
Clinical stability, persistence, relapse prevention, and management of breakthrough symptoms in patients receiving LAIs
Switching oral antipsychotics to long-acting injectable antipsychotics
Schizophrenia burden of illness and the impact of treatment adherence on outcomes, physical comorbidities, continuity of care, and healthcare utilization
Shared decision-making and therapeutic alliance among patients, caregivers, and the treatment team to support individualized treatment planning and LAI adoption
Patterns of LAI utilization in communities and populations experiencing systemic inequities, including social determinants of health
LAI transition-of-care models across inpatient and outpatient settings, including administration best practices
Destigmatizing schizophrenia to promote compassion, engagement, and treatment acceptance
Education on third-generation antipsychotics, including safety, relapse prevention, and appropriate dosing in schizophrenia
Clinical use of LAIs in special populations and patients with significant medical and psychiatric comorbidities

Treatment Resistant Depression (Major Depressive Disorder in adults with inadequate response to 2 or more antidepressants)

TRD in Clinical Practice: Diagnosis, Disease Burden, and Early Identification
Glutamate and the Mechanistic Basis of TRD Treatment
The Role of APPs in the Identification and Management of TRD
Shared Decision-Making and Patient-Centered Care in TRD
Remission and Functional Recovery as Treatment Goals in TRD
Pharmacologic and Interventional Treatment Approaches in TRD
Relapse Prevention and Sustained Remission in TRD
Health Equity and Disparities in MDD and TRD Care

Oncology

Multiple Myeloma

Smoldering Multiple Myeloma & Newly Diagnosed

Risk Stratification and diagnostic criteria
New & emerging data
Transplant eligible/ineligible NDMM
Maintenance therapy
Understanding the role of MRD in defining or adapting duration of therapy
High Risk patients, including elderly and minority patients
Applying guideline based care for Triplet & Quad based therapy

Relapsed Refractory

MOA and clinical use of BCMA & GPRC5D targeting bispecific antibodies (BsAbs)
New & emerging data for novel combinations of CD-38 & BsAbs
Emerging data for bsab and early relapse (1-3 prior lines of therapy)
Optimal therapy for patient groups (high risk, elderly, etc)
Integration of BsAbs into practice
- RWE
- In patient/out-patient strategies for step up dosing
- Patient selection
Bridging therapy for BCMA CAR-T
- Comparison CD-19 CAR-T bridging strategies & BCMA strategies
New & emerging data in CAR-T therapy; data on use in earlier line of therapy, long term data and application to practice (including RWE & CT data)
Collaboration & Coordination between community & transplant centers
Sequencing of bispecifics and CAR-T
Patient Selection/Eligibility
- Optimal therapy for patient groups (high risk, elderly, etc)
AE mitigation and management
- BCMA CAR-T related Neurotoxicities (e.g., CRS, ICANS, Parkinsonian symptoms, SPD) mitigation and management and differentiation from CD-19 CAR-T AEs
Care Coordination (Academic/Community HCPs)
Outpatient Administration & Remote Monitoring

Acute Myeloid Leukemia

MOA, scientific rationale and clinical use of menin inhibitors for treatment ofAML
New & emerging data related to menin inhibitors including frontline combinations and the role of maintenance
New & emerging treatment options using menin inhibitors for treatment of RR AML
Menin inhibitor related AEs
NPM1 & KMT2A Driver mutations- recognizing the significance and impact on treatment options
- Role of mutational testing, interpretation of results, and implications for treatment decisions

Oncology- Solid Tumor

Bladder Cancer (BC)

Mechanism of action (MOA)
Management and prevention of adverse events
Shared decision-making to increase patient/HCP communication, patient adherence and outcomes
Novel bladder-sparing therapies and MOAs
Clinical Trial data
Collaboration and communication strategies among multidisciplinary teams to enhance patient outcomes (referrals)

Prostate Cancer (PC)

Current and new therapies for treatment for PC
Treatment intensification
Molecular pathways involved in different stages of prostate cancer
Management and prevention of adverse events
Clinical trial data (ORR, PFS, OS)
Dosing and Administration
Understand the strategies to address unmet needs for treating prostate cancer

Non-small Cell Lung (NSCLC)

Current and new therapies for treatment for NSCLC
Management and prevention of adverse events (Incorporating prophylactic supportive care)
Clinical trial data (ORR, PFS, OS)
Dosing and Administration
Shared decision-making to increase patient/HCP communication, patient adherence and outcomes

Head and Neck Squamous Cell Carcinoma

Current and new therapies for treatment for HNSCC
Mechanisms of treatment resistance in HNC
Management and prevention of adverse events
Clinical trial data (ORR, mPFS, mOS)
Dosing and Administration
Epidemiology and risk factors associated with HNC
Collaboration and communication strategies among multidisciplinary teams to enhance patient outcomes (referrals)

Colorectal Cancer

Current and new therapies for treatment for CRC
Management and prevention of adverse events
Clinical trial data (ORR, mPFS, mOS)
Dosing and Administration
Collaboration and communication strategies among multidisciplinary teams to enhance patient outcomes (referrals)

Immunology

Gastroenterology

Inflammatory Bowel Disease- Chrohn’s Disease & Ulcerative Colitis
Target Audience: GIs, RN, PA, NP, Pharmacists
IBD Disease state awareness, including fistulizing CD
Mechanism of Action (all anti-IL-23s are not the same)(1H 2027)
Mechanism of Action: icotrokinra first-in-class, targeted oral peptide (selectively binds to and blocks the IL-23R) (2H 2027)
Efficacy
- Early onset of action
- Endoscopic remission, deep remission, histo-endoscopic endpoints
- Transmural healing
- Special populations/clinically relevant subgroups including fistulizing disease, EIMs, disease by location
Safety
- Long-term Safety and persistence
- Short and long-term safety of IL-23 inhibitors
- Short & long-term safety of combination therapies
1^st line advanced therapy choice
Treatment sequencing
Early use of advanced therapies
- Symptom onset
- Treatment journey
- Negative impact of long-term steroids and/or inadequate treatment with steroids/IMMs delaying use of biologics
IV & SC routes of administration
Oral route of administration (2H 2027)
Mechanism of Disease: targeted oral peptides (2H 2027)
Sub-optimally-treated patients
Interpretation of clinical trials based on their design, especially ACCENT II vs FUZION (1H 2027); ICONIC-UC Ph3, ICONIC-CD Ph2 (2H 2027)
Cost Effectiveness
Combination therapy (eg JNJ-4804) (late 2H 2027)

Fellowships:

US Fellowship Academic Institutions
Nurses- (APPs)NPs/PAs

Dermatology

Psoriasis (PsO)

Treatment gaps in the management of PsO
Diagnosis, differential diagnosis, and management of PsO
Evolution of the treatment paradigm for PsO
Assess the severity of PsO
Recent updates in guidelines and treatment practices for treatment of PsO and impact in the real-world
Topical failure criteria and treatment options
Address gaps in care in underserved/undertreated patients with PsO
Support ongoing professional development with fellowships and educational programs
Clinical trial or real-world data for emerging oral therapies in PsO management including head-to-head comparisons and long-term data
Current and emerging therapies for PsO, with a focus on IL-23 inhibitors, orals, their MOA, and the latest safety, efficacy, or real-world evidence
Clinical and immunologic factors involved in the progression of PsO to PsA
Shared inflammatory pathways linking the gut, skin, and joints to support integrated patient care.
Include patient voice, patient satisfaction, and shared decision making related to treatments for PsO.

Rheumatology

Psoriatic Arthritis (PsA)

Treatment gaps in the management of PsA
Diagnosis and management of PsA, including various manifestations/subtypes of PsA
Early diagnosis, identification, and management of Axial PsA
PsA Disease State Awareness
Clinical trial efficacy and safety data in PsA management
Current guideline developments
Support ongoing professional development with fellowships and educational programs
Early diagnosis and identification of suboptimally-treated patients with PsA, and axial PsA
Efficacy and safety of advanced therapies in the treatment of patients with PsA
Structural damage and the importance of early detection and effective treatment
Clinical and immunologic factors involved in the progression of PsO to PsA
Shared inflammatory pathways linking the gut, skin, and joints to support integrated patient care.

Ankylosing Spondylitis (AS)

AS Disease state awareness
Clinical, imaging, and genetic differences between AS and Axial PsA
Clinical trial efficacy and safety data in AS management
Current guideline developments
Support ongoing professional development with fellowships and educational programs
Early diagnosis and identification of suboptimally-treated patients with AS
Efficacy and safety of advanced therapies in the treatment of patients with AS

Rheumatoid Arthritis (RA)

RA Disease state awareness
Clinical trial efficacy and safety data in RA management
Current guideline developments
Support ongoing professional development with fellowships and educational programs
Early diagnosis and identification of suboptimally-treated patients with RA
Efficacy and safety of advanced therapies in the treatment of patients with RA

Sjögren’s Disease (SjD)

SjD Disease state awareness
Sjögren’s MOD and FcRN biology
FcRN as a targeted mechanism of action for SjD versus deep B-cell depletion
Clinical trial efficacy and safety data in SjD management
Current guideline developments
Support ongoing professional development with fellowships and educational programs
Early diagnosis and identification of suboptimally-treated patients with SjD
Efficacy and safety of advanced therapies in the treatment of patients with SjD

Autoantibody

Myasthenia Gravis

Educate Neurologists and Neuromuscular specialists on within and between class differences in targeted therapies for the treatment of gMG, including MOA, safety, sustained efficacy, corticosteroid reduction, and pre-drug initiation requirements.
Raise awareness for recent approvals of targeted therapies for the treatment of pediatric and adolencent gMG patients, and educate neuro/neuromuscular pediatric focus providers on the MOA and practical aspects of targeted treatment selection considerations and use in this population.
Educate the broader MG treating community on the benefits and practical aspects of quantitative monitoring of gMG disease in real-world practice, how to use measures to assess treatment response and relevant timecourses to assess response for various available treatments, and how to set and evaluate appropriate treatment goals using validated measures.
Highlight the importance of shared decision making and considering patient experience/goals when selecting treatment options.

wAIHA

Increase recognition of wAIHA and support timely, accurate diagnosis using standardized evaluation of hemolysis, direct antiglobulin test results, disease severity, primary versus secondary causes.
Educate hematologists and other clinicians involved in wAIHA care on disease pathogenesis, including the role of pathogenic IgG autoantibodies, Fc-mediated red blood cell clearance, and complement activation, and connect these mechanisms to emerging targeted treatment approaches.
Improve evidence-based treatment selection and sequencing across the patient journey, including corticosteroid stewardship, definitions of response, treatment failure, relapse and steroid dependence, escalation criteria, active surveillance and sustained management.
Build clinician competence in interpreting clinical evidence for established and emerging wAIHA therapies, including mechanism of action, patient selection, hemoglobin response, speed and durability of response, rescue therapy, steroid reduction, fatigue, safety, and practical considerations for use.
Promote individualized, shared decision-making that incorporates disease severity, prior treatment, comorbidities, treatment goals and burden including safety concerns for risk of infection, route and frequency of administration, patient preferences, fatigue, quality of life, and the need for sustained disease control.

Priority gMG audiences include neuromuscular specialists, and other neurologists who manage advanced therapies, with expanded education for general and community neurologists, pediatric neurologists/neuromuscular specialists, and advanced practice providers.

Priority wAIHA audiences include benign and community hematologists, hematologist-oncologists, pediatric hematologists, advanced practice providers, nurses, pharmacists, transfusion medicine specialists, infusion care teams, emergency and inpatient clinicians, and other healthcare professionals involved in recognizing or managing wAIHA.